A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures
NCT01777139
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
DRUG:
Retigabine IR
Sponsor
GlaxoSmithKline